Advertisement

Medical Oncology

, 33:76 | Cite as

Non-surgical organ preservation strategies for locally advanced laryngeal tumors: what is the Italian attitude? Results of a national survey on behalf of AIRO and AIOM

  • D. AlterioEmail author
  • P. Franco
  • G. Numico
  • L. Licitra
  • M. Cossu Rocca
  • A. Ferrari
  • C. Pinto
  • E. G. Russi
  • U. Ricardi
  • B. A. Jereczek Fossa
Original Paper

Abstract

Chemoradiotherapy is the treatment mostly used as organ preservation (OP) strategy worldwide in advanced laryngo-hypopharyngeal cancer. Due to the not homogeneous results of the literature data regarding the pre-treatment assessment and treatment schedule in this setting of patients, the Italian societies of radiation oncology and medical oncology surveyed (by an online survey) their memberships regarding the Italian attitude on larynx preservation in clinical practice. The survey outline addressed different items such as: demographics (11 items), pre-treatment evaluation (12 items), treatment schedules (10 items) and outcomes (3 items). The survey was filled in by 116 clinical oncologists (64 % radiation and 36 % medical oncologists). Results highlighted that pretreatment evaluation was not homogeneous among the respondents. The treatment of choice for the OP program resulted the concurrent chemoradiotherapy (66 %). Induction chemotherapy was proposed mostly in case of aggressive tumors such as advanced stage (T4 or N3) and/or unfavorable primary sites (hypopharynx). Moreover, after induction chemotherapy, for responders patients most participants (46 %) proposed concurrent chemoradiotherapy, while 18 and 19 % proposed radiotherapy alone or radiotherapy and cetuximab, respectively. For patients with stable disease after induction chemotherapy, the respondents declared to suggest surgery, radiotherapy and cetuximab or radiotherapy alone in 38, 32 and 15 % of cases, respectively. Results of the present survey highlighted the variability of therapeutic approaches offered in clinical practice for patients candidate to a larynx OP program. Analysis of abovementioned results may give the chance to modify some clinical attitudes and create the background for future clinical investigation in this field.

Keywords

Laryngeal tumor Organ preservation Survey Chemoradiotherapy 

Notes

Compliance with ethical standards

Conflict of interest

None.

Supplementary material

12032_2016_781_MOESM1_ESM.pdf (212 kb)
Supplementary material 1 (PDF 211 kb)

References

  1. 1.
    Denaro N, Russi EG, Lefebvre JL, et al. Systematic review of current and emerging approaches in the field of larynx preservation. Radiother Oncol. 2014;110:16–24.CrossRefPubMedGoogle Scholar
  2. 2.
    Forastiere A, Weber RS, Trotti A. Organ preservation for advanced larynx cancer: issues and outcome. J Clin Oncol. 2015;33:3262–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Lefebvre J-L, Ang KK. Larynx preservation clinical trial design: key issues and recommendations—a consensus panel summary. Head Neck. 2009;31:429–41.CrossRefPubMedGoogle Scholar
  4. 4.
    Bradford CR, Wolf GT, Carey TE, et al. Predictive markers for response to chemotherapy, organ preservation, and survival in patients with advanced laryngeal carcinoma. Otolaryngol Head Neck Surg. 1999;121:534–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349:2091–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Rosenthal DI, Mohamed ASR, Weber RS. Long term outcome after surgical or non-surgical initial therapy in patients with T4 squamous cell carcinoma of the larynx; a 3-decade survey. Cancer. 2015;15:1608–19.CrossRefGoogle Scholar
  7. 7.
    Bussu F, Paludetti G, Almadori G, et al. Comparison of total laryngectomy with surgical (cricohyoidopexy) and non-surgical organ-preservation modalities in advanced laryngeal squamous cell carcinoma; a multicenter retrospective analysis. Head Neck. 2013;35:554–79.CrossRefPubMedGoogle Scholar
  8. 8.
    Worden FP, Moyer J, Lee JS. Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion. Laryngoscope. 2009;119:1510–7.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Wagner MM, Curé JK, Caudell JJ. Prognostic significance of thyroid or cricoidcartilage invasion in laryngeal or hypopharyngeal cancer treated with organ preserving strategies. Radiat Oncol. 2012;. doi: 10.1186/1748-717X-7-219.Google Scholar
  10. 10.
    Mucha-Małecka A, Składowski K. High-dose radiotherapy alone for patients with T4-stage laryngeal cancer. Strahlenther Onkol. 2013;189:632–8.CrossRefPubMedGoogle Scholar
  11. 11.
    The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation in patients with advanced laryngeal cancer. N Eng J Med. 1991;324:1685–90.CrossRefGoogle Scholar
  12. 12.
    MacKenzie R, Frassen E, Balogh J, et al. The prognostic significance of tracheostomy in carcinoma of the larynx treated with radiotherapy and surgery for salvage. Int J Radiat Oncol Biol Phys. 1998;41:43–51.CrossRefPubMedGoogle Scholar
  13. 13.
    Richard JM, Sancho-Garnier H, Pessey JJ, et al. Randomized trial of induction chemotherapy in larynx carcinoma. Oral Oncol. 1998;34:224–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Lefebvre J-L, Ang KK. On behalf of the larynx preservation consensus panel Larynx preservation clinical trial design; key issue and recommendations-a consensus panel summary. Int J Radiat Oncol Biol Phys. 2009;73:1293–303.CrossRefPubMedGoogle Scholar
  15. 15.
  16. 16.
  17. 17.
  18. 18.
    Pignon J-P, le Maitre A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92:4–14.CrossRefPubMedGoogle Scholar
  19. 19.
    Schindler A, Denaro N, Russi EG. Dysphagia in head and neck cancer patients treated with radiotherapy and systemic therapies: literature review and consensus. Crit Rev Oncol Hematol. 2015;96:372–84.CrossRefPubMedGoogle Scholar
  20. 20.
    Lagha A, Chraiet N, Labidi S, et al. Larynx preservation: what is the best non-surgical strategy? Crit Rev Oncol Hematol. 2013;88:447–58.CrossRefPubMedGoogle Scholar
  21. 21.
    Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013;31:845–52.CrossRefPubMedGoogle Scholar
  22. 22.
    Lefebvre J-L, Rolland F, Tesselaar M, et al. Phase 3 randomized trial on larynx preservation comparing sequential versus alternating chemotherapy and radiotherapy. J Natl Cancer Inst. 2009;101:142–52.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Lefebvre JL, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cooperative Group. J Nat Cancer Inst. 1996;88:890–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Lefebvre JL, Andry G, Chevalier D, et al. Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carinoma: 10-year results of EORTC trial 24891. Ann Oncol. 2012;23:2708–14.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. Natl Cancer Inst. 2009;101:498–506.CrossRefGoogle Scholar
  26. 26.
    Posner MR, Norris CM, Wirth LJ, et al. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. Ann Oncol. 2009;20:921–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–78.CrossRefPubMedGoogle Scholar
  28. 28.
    Lefebvre JL, Pointreau Y, Rolland F, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol. 2013;31:853–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • D. Alterio
    • 1
    Email author
  • P. Franco
    • 2
  • G. Numico
    • 3
  • L. Licitra
    • 4
  • M. Cossu Rocca
    • 5
  • A. Ferrari
    • 1
  • C. Pinto
    • 6
  • E. G. Russi
    • 7
  • U. Ricardi
    • 2
  • B. A. Jereczek Fossa
    • 1
    • 8
  1. 1.Department of Radiotherapy, Advanced Radiotherapy CenterEuropean Institute of OncologyMilanItaly
  2. 2.Department of Oncology, Radiation OncologyUniversity of TurinTurinItaly
  3. 3.Medical Oncology UnitOspedale U. PariniAostaItaly
  4. 4.Head and Neck Medical Oncology UnitFondazione IRCCS Istituto Nazionale TumoriMilanItaly
  5. 5.Genitourinary Unit, Division of Medical OncologyEuropean Institute of OncologyMilanItaly
  6. 6.Medical OncologyIRCCS-Arcispedale S. Maria NuovaReggio EmiliaItaly
  7. 7.Department of Radiation OncologySanta Croce General HospitalCuneoItaly
  8. 8.University of MilanMilanItaly

Personalised recommendations